Ahmed Bahi on Lina Merghani’s Critique of Early Withdrawal of Aspirin after PCI
Ahmed Bahi, Critical Care Pharmacist Specialist in Trauma Services at Hamad Medical Corporation, shared on LinkedIn:
”Exciting News in Cardiovascular Research!
I’m thrilled to share that I recently had the opportunity to supervise my pharmD student Lina Merghani in critique of a groundbreaking study published in NEJM focused on the ”early withdrawal of aspirin after percutaneous coronary intervention (PCI) in acute acute coronary syndrome (ACS)”..
In my critique, Dr Lina highlighted benefit vs risk of stopping aspiring after acute ACS.
I want to commend our PharmD student for their hard work and dedication to advancing care for trauma patients.
Your contributions are paving the way for improved patient outcomes.
Let’s continue to push the boundaries of knowledge and improve the lives of our patients.”
Read the full article in NEJM.
Article: Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes
Authors: NEO-MINDSET Trial Investigators
Stay updated with Hemostasis Today.
-
Sep 20, 2026, 05:17Maxime Dely: When ABO Compatibility Isn’t Enough for Safe Transfusion
-
Sep 20, 2026, 04:54William Aird: What Does a Complete History and Physical Really Mean?
-
Sep 20, 2026, 04:34Hons Saurabh Kaushik: Why Uncontrolled LDL Can Be Harmful
-
Sep 20, 2026, 03:58Salih Ehsan: The Complexities of HbF and HbA2
-
Sep 20, 2026, 03:22The Voices of People Living With Bleeding Disorders – EHC
-
Sep 20, 2026, 01:18Sebastian Mafeld: Has 2026 Changed How We Treat Pulmonary Embolism?
-
Sep 20, 2026, 01:16Pall T. Onundarson: DOACs – Monitoring, Tailoring Dose and Identifying Problems
-
Sep 20, 2026, 01:15Thierry Fumeaux: From Efficacy to Effectiveness – The Value of Real-World Evidence
-
Sep 20, 2026, 01:14Said El Shamieh: VEGFA Genetic Variants and Bleeding Risk During Warfarin Therapy